pharmaceuticals

Wall Street was dead wrong on this one…

Boy, did Marc dodge a bullet on this one…

Can its latest results salvage its valuation?

Save hundreds (or even thousands) on healthcare each year!

This pandemic darling isn’t so popular anymore.

Will falling free cash flow end this drug giant’s streak?

There are opportunities for biotech investors to profit at each stage of clinical trials.

With its low payout ratio and booming free cash flow, this pet pharmacy is a dividend investor’s best friend.

Pfizer’s struggles with free cash flow and dividend cuts may have a silver lining if its growth meets expectations.